Mavacamten is a cardiac myosin inhibitor indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. MedsAcross supplies Mavacamten for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
CAMZYOS is indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. CAMZYOS is a cardiac myosin inhibitor indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Source: US FDA prescribing information
Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. Mavacamten shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In HCM patients, myosin inhibition with mavacamten reduces dynamic LVOT obstruction and improves cardiac filling pressures.
Source: US FDA prescribing information
Dosage must be individualized based on clinical status and echocardiographic assessment of patient response. Refer to the Full Prescribing Information for instructions.
Source: US FDA prescribing information
CAMZYOS is contraindicated with concomitant use of: • Strong CYP2C19 inhibitors • Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers • Strong CYP2C19 inhibitors. • Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers.
Source: US FDA prescribing information
Boxed warning (risk of heart failure camzyos): reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt CAMZYOS if LVEF is <50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status. • Heart Failure: Consider interruption of CAMZYOS in patients with intercurrent illness. • Drug Interactions Leading to Heart Failure or Loss of Effectiveness: Advise patients of the potential for drug interactions including with over-the-counter medications. • Embryo-Fetal Toxicity: May cause fetal harm. Advise females of reproductive potential to use effective contraception until 4 months after the last dose.
Source: US FDA prescribing information
The following adverse reaction is discussed in other sections of the labeling: • Heart failure Adverse reactions occurring in >5% of patients and more commonly on CAMZYOS than on placebo were dizziness (27%) and syncope (6%).
Source: US FDA prescribing information
• Weak to moderate CYP2C19 inhibitors and moderate to strong CYP3A4 inhibitors: May increase risk of heart failure. If initiating an inhibitor, CAMZYOS dose reduction and additional monitoring are required. • Negative inotropes: Close medical supervision and LVEF monitoring is recommended if a negative inotrope is initiated, or the dose of a negative inotrope is increased. Avoid certain combinations of negative inotropes.
Source: US FDA prescribing information
Storage Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Mavacamten, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Camzyos 10 mg capsuleOral | Myokardia | US FDA | Available on request |
| Camzyos 15 mg capsuleOral | Myokardia | US FDA | Available on request |
| Camzyos 2.5 mg capsuleOral | Myokardia | US FDA | Available on request |
| Camzyos 5 mg capsuleOral | Myokardia | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 4 presentations of Mavacamten and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Mavacamten, including Camzyos.
Yes. The US FDA first approved Mavacamten on 28 April 2022, according to Drugs@FDA.
Yes. Mavacamten has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Mavacamten is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Mavacamten is classified under ATC code C01EB (Heart rhythm and heart failure medicines, subgroup C01E, subgroup C01EB).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.